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Abstract
Objective: A promising strategy in regenerative endodontics is the combination of 
human dental pulp stem cells (hDPSCs) with an appropriate biomaterial substrate. 
The effects of zinc and zinc containing bioactive glasses (ZnBGs) on hDPSCs have 
been characterised in this study. 
Methods: ZnBGs were designed and produced. Then the odontogenic differentiation 
and mineralisation potential of hDPSCs upon ZnBGs treatment were investigated.
Results: Free Zn ions (0-5 ppm) enhanced proliferation and alkaline phosphatase 
(ALP) activity of hDPSCs. Further, ZnBGs conditioned medium (ZnBG-CM) 
increased the production and secretion of odontogenic markers: dentine 
sialophosphoprotein (DSPP), dentine matrix protein 1 (DMP-1). In addition, we 
identified that mRNA expression of the osteogenic markers RUNX2, OCN, BSP, 
BMP-2, MEPE and ON was increased following treatment with ZnBG-CM. Long term 
treatment with ZnBG-CM increases the formation rate of mineralised nodules (similar 
to hydroxyapatite, Ca:P=1.6), as confirmed by scanning electron microscopy 
combined with energy dispersive X-ray spectroscopy (SEM-EDX). Lastly, the 
administration of ZnBG-CM induces VEGF expression. 
Significant: These findings implicate that ZnBG would be beneficial in regenerative 
endodontics and could influence the way present Zn containing clinical products are 
used.
Zinc Bioglasses Regulate Mineralisation in Human 
Dental Pulp Stem Cells
1. Introduction 
The high incidence of tooth decay and tooth loss combined with the limited 
regeneration capacities of dental tissues necessitates the development of novel 
strategies for dental practices [1]. Human dental pulp stem cells (hDPSCs) are 
a mesenchymal stem cell (MSC) population [2, 3]. Analogous to MSCs derived 
from bone marrow (BMSCs), hDPSCs can form alizarin red-positive mineralised 
deposits, physiologically similar to hydroxyapatite (HA) [2, 4]. Thus, experiments 
have been conducted to evaluate the value of hDPSCs in the repair of bone 
defects [5-7]. However, numerous studies have demonstrated that hDPSCs 
have a greater ability to differentiate into odontoblasts compared to BMSCs [2, 
8]. Co-transplanting cultured hDSPCs with HA/TCP particles, into 
immunocompromised mice, led to the vascularisation of a fibrous pulp tissue 
surrounded by a layer of odontoblast-like cells, cells had extended tubular 
structures that resembling a dentine-like structure [2, 8]. In contrast, a lamellar 
bone structure with associated adipose tissue was formed by human BMSCs 
under the same experimental condition [2]. These findings clearly demonstrate 
distinct tissue regeneration capacities of hDPSCs and BMSCs, which appear to 
have maintained a level of epigenetic memory of their tissue origin [2]. 
Somewhat unsurprisingly then, hDPSCs is the preferred derivation of cells for 
dental tissue engineering.
The fundamental concept in hard tissue engineering lies in combining a scaffold 
with living cells to repair damaged tissue [9]. Scaffolds provide a suitable 
environment for cell attachment, proliferation, differentiation and to promote bio-
mineralisation [10]. A significant challenge regarding scaffold usage is the 
choice of a suitable material. A broad range of materials, natural or synthetic 
polymers and inorganics, have been designed as scaffolds for dentin-pulp 
regeneration [11]. Bioactive glasses (BGs) are a promising choice for repair and 
reconstruction of hard tissues, such as bone and dentine [12, 13]. BGs can form 
hydroxyapatite (HA) quickly, is biocompatible and can deliver ‘therapeutic ions’ 
[12, 14]. 
In dental practice, the use of zinc (Zn) is mostly favoured owing to its 
bacteriostatic and cariostatic properties [15]. For example, Znoxide eugenol 
(ZOE), Zn oxyphosphate (ZOP), and Zn polycarboxylate (ZPC) are widely used. 
However, despite the clinical advantages, the dentinogenic benefits of Zn have 
yet to be determined. Accordingly, we have focused on Zn and Zn containing 
BGs (ZnBGs) to characterise their effects on hDPSCs. 
2. Materials and methods
2.1. Bioactive glass synthesis and characterisation
ZnBGs (compositions are shown in Fig.2A) were synthesised by the melt-
quench route [16]. Glass frits were grounded and sieved to powders ≤ 38µm. 
The particle size and amorphous nature was confirmed by master particle size 
analyser and X-ray diffraction (XRD). ZnBGs powders were characterised as 
described previously [17]. Briefly, 75mg of BGs powder (≤ 38 µm) was added to 
50 ml Tris buffer and incubated on an orbital shaker (60 rpm at 37 °C). Post 
shaking, the pH values were recorded. The solution was filtered, diluted by a 
factor of ten in distilled H2O and acidified with 69% nitric acid (final 
concentration 2%) prior to determining the elemental concentrations of calcium 
(Ca), phosphorus (P), silica (Si), and zinc (Zn) using an inductively coupled 
plasma-optical emission spectrometer (ICP-OES). The residual powders were 
dried overnight and analysed to evaluate the extent of apatite formation using 
XRD, and Fourier transform infrared spectroscopy (FTIR). 
2.2. Cell culture 
Human dental pulp stem cells (hDPSCs, Lonza) were cultured in Dulbecco's 
Modified Eagle Medium (DMEM, Lonza) supplemented with 10% fetal calf 
serum (FCS) and antibiotics (10U/L penicillin and 100mg/L streptomycin) in a 
humidified atmosphere with 10% CO2 at 37 °C. 
Free ionic Zn (0.5, 1, 5, 10 and 20 ppm) was added as ZnCl2. ZnBG conditioned 
medium (ZnBG-CM) was prepared by immersing 75mg of glass powders in 
50ml DMEM for set periods of time. Before being added to the cells, ZnBG-CM 
was filter-sterilized, serum and antibiotics were added and equilibrated to 37oC, 
10% CO2 in an incubator. 
Cells between passages 3-5 were used in all experiments. For cell proliferation, 
MTT and ALP activity assays, 1000 cells/well were seeded in 96-well plates and 
cultured for 1, 4, 7 and 10 days. 1×105cells/dish and 2×104cells/well were 
placed in 10cm dishes and 6-well plate for Western blot and qPCR studies, 
respectively. 5×103 cells were seeded onto sterilised coverslips and placed in 
12-well plates for immunocytochemistry. 24-wells plate with 5×103 cells/well 
was used for the mineralisation study. 
2.3. MTT activity assay
The MTT activity assay reflects mitochondrial activity-an indication of viable 
cells. After rinsing twice with PBS, 50μl of MTT solution (5mg/ml MTT in PBS) 
was added to cell cuture and incubated for 4 hrs at 37°C. After this, medium 
was removed and the formazan was solubilised in 100μl dimethyl sulfoxide 
(DMSO). The absorbance of the solubilised formazan supernatant was 
measured at 560nm. 
2.4. Quantitative assay of ALP activity
Alkaline phosphatase (ALP) activity was measured by adding 100μl of ALP 
reaction solution (20mg 4-Nitropheyl-phosphate disodium salt hexahydrate 
tablet dissolved in 8ml Tris buffer solution (pH=9.5) containing 15μl of 2M MgCl2) 
to cell lysate, incubated in the dark at 37oC for 1 hr. Afterwards, the reaction 
was stopped by adding 50 μl of 1M NaOH. The absorbance of the supernatant 
was measured at 405nm and ALP activity was calculated according to a 
standard curve (Fig.S1). 
2.5. Crystal violet staining
Cells were fixed with 10% neutral buffered formalin for 15 min, rinsed twice with 
PBS and stained in 0.5% (w/v) crystal violet for 15 min at room temperature. 
Before visualising, the unbound stains were removed by extensive washing in 
PBS.  
2.6. Western Blot analysis 
Cell pellets were re-suspended in RIPA buffer (containing 1% Triton X-100 and 
1% cocktail proteinase inhibitors) and the protein content measured using DC™ 
Protein Assay. Intracellular expression of dentin sialophosphoprotein (DSPP), 
dentin matrix acidic phosphoprotein 1 (DMP-1) and vascular endothelial growth 
factor (VEGF) was evaluated by Western blotting using indicated antibodies 
(Table.A.1) on a PVDF membrane. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as the loading control. Cell culture 
supernatant was also collected and analysed for DSPP and DMP-1 secretion, 
Coomassie blue was used to visualise sample separation. The band densities 
were quantified by ImageJ software.
2.7. Immunocytochemistry
4% paraformaldehyde in PBS was used to fix the cells. Subsequently, cells 
were permeablised with 0.1% Triton X-100 for 10 min, and incubated with 10% 
goat serum for 30 min to block nonspecific binding. Following 1 hr incubation in 
primary antibody (Table.S1) at room temperature, cells were washed and 
incubated with secondary antibody for 1 hr and counter stained with DAPI. 
Finally, the cells were mounted on slides and viewed under confocal 
microscopy (LSM710, Zeiss). The images were then analysed with ImageJ 
software.
2.8. Quantitative real-time polymerase chain reaction-qPCR 
Message RNA (mRNA) was isolated from cells with Dynabeads® (Thermo 
Fisher Scientific) and reverse-transcribed into cDNA using Transcriptor cDNA 
Synthesis Kit (Roche). The forward and reverse primers used for PCR were 
designed by Roche universal probe library according to the complementary 
DNA sequences available in GenBank (Table.S2). qPCR amplifications were 
performed on LightCycler 480 qPCR system (Roche) using LightCycler® 480 
SYBR Green I Master. For each PCR reaction, 2μl of 10 fold-diluted cDNA was 
used for amplification of the target genes. The thermal cycling conditions were 
as follows: 95°C for 5 min and 55 cycles of 95°C for 10s, 60°C for 6s, 72°C for 
6s, 76°C for 1s. Relative expression levels of runt-related transcription factor 2 
(RUNX2), osteonectin (ON), osteocalcin (OCN), bone sialoprotein (BSP), matrix 
extracellular phosphoglycoprotein (MEPE), and bone morphogenetic protein 2 
(BMP-2) were determined with reference to GAPDH. 
2.9. Alizarin Red S staining
After 3, 4 and 5 weeks culture, cells were fixed in 4% glutaraldehyde for 30min 
and stained with 2% Alizarin Red S (Sigma-Aldrich) for 1 hr at room 
temperature. After three washes in dH2O to remove unbound stain, samples 
were air-dried and photographed. For quantification, the bound stain was 
extracted with 10% cetylpyridinum chloride, and the absorbance of solution was 
measured at 560 nm. 
2.10. Scanning electron microscope (SEM)
Cells were fixed in 2.5% glutaraldehyde for 1 hr and dehydrated in graded 
ethanol (50%, 70%, 80%, 90%, 95%, and 100%), followed by critical-point 
drying with hexamethyldisilazane. The samples were coated with carbonate and 
viewed using SEM with an energy-dispersive X-ray (EDX) detector operated 
from 10-20 kV to scan and analyse mineralised nodule formation and 
composition.
2.11. Statistical analysis
Statistical analysis was performed using GraphPad Prism 5. All data were 
collected from three independent experiments and presented as mean ± 
standard deviation (SD). Differences were considered significant at p<0.05, 
determined using one-way ANOVA with Bonferroni’s post hoc multiple 
comparison test. 
3. Results
3.1. Low dose Zn increases hDSPCs proliferation and ALP activity
Cells were treated with Zn (0.5 to 20 ppm) for 1, 4, 7 and 10 days. Zn at low 
concentrations (0.5 and 1 ppm) showed no significant effect on cell proliferation 
(Fig.1A) as determined by MTT activity assays. Zn at 5 ppm significantly 
increased (*p<0.05) cell proliferation. However, Zn at high doses (10 and 20 
ppm) significantly reduced (*p<0.05) both cell proliferation. A significant 
increase (*p<0.05) in ALP activity is observed at low concentrations of Zn (0.5 
and 1 ppm) treatment for 7-10 days (Fig.1B). At 20 ppm, Zn reduced ALP 
activity (Fig.1B) due to increased cytotoxicity as visualised by crystal violet 
staining (Fig.1C).
3.2. Characterisation of ZnBGs 
The amorphous nature of the ZnBGs was indicated by broad peaks in the XRD 
patterns (Fig.2B). Similar particle size distribution was confirmed by particle size 
analysis (Fig.S2A). 
To evaluate bioactivity of the ZnBGs, immersion in Tris buffer was performed. 
An increase in pH was measured after immersion (Fig.S2B). The XRD and 
FTIR studies confirmed that Zn incorporation retards apatite formation in a 
dose-dependent manner (Fig.2C-F). Consistent with XRD findings, the FTIR 
data also suggested that Zn delays apatite formation (Fig.S3). ICP-OES 
analysis revealed rapid release of P and Ca ions from the glass within the first 6 
hrs of immersion, these were then incorporated into apatite, hence the reduction 
of measurable levels. The concentration of Si increased continuously due to the 
continuous glass dissolution. Interestingly, no particular release pattern was 
observed for Zn (Fig. 2G-J), but the Zn concentration in all samples was less 
than 1ppm.
3.3. ZnBG-CM regulates hDPSC behaviour and processing of DSPP and 
DMP-1
hDPSCs were treated with ZnBG-CM. MTT assay demonstrated that ZnBG-CM 
has no significant effect on cell proliferation after 1 and 4 days of treatment. Cell 
proliferation was increased in Zn1, Zn2 and Zn3 BG-CM treatment groups by 
day 7 and 10. Enhanced ALP activity was detected in hDPSCs following 
treatment with Zn3 BG-CM by day 1. However, by day 7 and 10, a significant 
increase (*p<0.05) in ALP activity was detected in all ZnBG-CM treatments 
when compared with the control group (Fig. 3B). 
To further investigate the influence of ZnBGs on the odontogenic differentiation 
of hDPSCs, the regulation of two odontogenic markers - DSPP and DMP-1 was 
determined by Western blot and immunocytochemistry. As shown in Fig.3C, 
multiple bands were detected in DSPP and DMP-1 immunoblotting, that are 
indicative of protein processing as reported previously [18]. Densitometry 
analysis revealed that intracellular DSPP levels were significantly increased 
(*p<0.05) upon all ZnBG-CM treatment and intracellular DMP-1 levels were only 
enhanced in Zn2 and Zn3 BG-CM treatment for 7 days in culture. However, 
prolonged treatments that extend for 14 days suggested a reduction in 
intracellular DSPP and DMP-1 levels (Fig.3D). Immunoblotting of cell culture 
supernatant reflected the secretion of these two proteins (Fig.3E), where only 
DMP-1, but not DSPP, secretion is significantly increased (*p<0.05) following 
ZnBG-CM treatment (Fig.3F). 
Immunocytochemistry and confocal microscopy analysis demonstrated that 
DSPP is localised to nucleus and perinuclear region (confirmed by co-staining 
with the Golgi marker GM130, Fig.4A and C). Further, DSPP localisation to 
Golgi was induced following ZnBG-CM treatment (Fig.4B and C). DMP-1 is 
shown to be localised in both cytosol and nucleus (Fig.4A) and no change in its 
localisation pattern is induced by ZnBG-CM treatment (Fig.S4). 
3.4. ZnBG induces mineralisation of hDPSCs 
The mineralisation potential of hDPSCs following ZnBG-CM treatment was 
assessed by Alizarin Red S that stains Ca2+ deposits red (Fig.5A). 
Quantification of the staining demonstrated significant increases (*p<0.05) in 
the staining induced by treatment with Zn1, Zn2 and Zn3 BG-CM by week 3, 4 
and 5 in comparison to the glass free control group. SEM scans revealed that 
the mineralised nodules generated by hDPSCs were between 50 and 100µm in 
diameter and were raised from the culture surface (Fig.5C). EDX spectra for 
calcium and phosphate content in the mineralised nodules indicated a ratio of 
Ca:P similar to that of hydroxyapatite (~1.6, Fig.5C).
3.5. ZnBG modulates mineralisation-associated gene expression
Further regulation of mineralisation-related differentiation markers of hDPSCs 
was investigated by qPCR. This analysis revealed up-regulation of BSP and 
MEPE by day 7 and 14 following all conditions of ZnBG-CM treatment (Fig. 5G 
and H). High expression levels of RUNX2 and BMP-2 were detected for Zn1, 
Zn2 and Zn3 groups but not Zn0 group. Differential expression was observed 
for ON, when compared to other groups, and OCN is increased only by groups 
Zn0 and Zn3 at day 7. However, by day 14, the mRNA level of all the genes 
was up-regulated following ZnBG-CM treatment irrespective of the Zn content 
(Fig.5D-I). 
3.6. ZnBG modulation of VEGF levels
Following ZnBG-CM treatment immune blotting and densitometry analysis 
revealed that Zn1 and Zn3 groups clearly enhanced intracellular VEGF levels in 
hDPSCs after 7 days. Furthermore, by day 14 the expression of VEGF was 
significantly increased (*p<0.05) in all ZnBG-CM treatments (Fig 5J-K). 
4. Discussion
The use of 45S5® BG in regenerative endodontics for pulp capping 
demonstrated the formation of a reparative dentine bridge [19, 20]. The 
amorphous BG is generally more soluble and reactive than crystalline materials, 
such as calcium phosphate, thereby enhancing the bioactivity of the material. In 
addition, BGs can be manufactured to release ‘therapeutic’ ions, which may 
induce accelerated formation of mineralised tissues. As Zn is already widely 
used in dentistry, we have investigated the effect of ZnBGs on differentiation 
and mineralisation of hDPSCs. 
Initially, the safe range of free Zn ion was accessed in cultures of hDPSCs. Cell 
proliferation and ALP activity assays suggested that low dose Zn, from 0 to 5 
ppm, is not cytotoxic and induces the proliferation and differentiation of hDPSCs. 
High concentrations (10 and 20ppm) are toxic (Fig. 1). These findings 
suggested that ZnBG might also be able to positively modulate hDPSCs 
odontogenic behaviour. 
The influence of Zn on the bioactivity process and its role in BG structure has 
been extensively debated in literature [21]. ZnO can either act as a modifier 
leading to a decrease in surface area and pore size of the BG [22]. ZnO can 
also act as an intermediate oxide forming covalent links between adjacent SiO4 
tetrahedra [23] to create a more stable glass structure. In this study, Zn was 
added to the BGs assuming that it behaves entirely as an intermediate oxide. 
The ZnBGs were successfully synthesised as amorphous structures. The 
bioactivity of these ZnBGs was quantified (assessed by apatite formation) when 
immersed in a relevant physiological fluid. [24]. XRD and FTIR findings both 
confirmed that Zn addition to BG delays the apatite formation in a dose-
dependent manner (Fig. 2). This agrees with previous findings, where delayed 
apatite formation was due to an increase in the network polymerisation with the 
incorporation of Zn [25]. 
To determine any biological effect, ZnBG-CMs were used in cell culture. At 
early time points (1 and 4 days), ZnBG-CMs showed no effect on cell 
proliferation, thereafter increased cell proliferation was observed by day 7 and 
10 (Fig. 3). These findings indicate that these novel ZnBGs have no significant 
cytotoxic effects on hDPSCs, confirming the possible utilisation of these 
materials in tissue repair. The observed increase in ALP activity with ZnBG 
treatment over time indicates the differentiation potential of hDPSCs and 
confirmed by the subsequent increase in mineralisation (Fig. 3). 
Protein levels of the odontogenic markers DSPP and DMP-1 were quantified to 
determine odontogenic differentiation of hDPSCs following ZnBG-CM treatment 
(Fig. 3). DSPP and DMP-1 are both involved in the nucleation and formation of 
HA during dentine formation [26]. Multiple bands were observed in DSPP and 
DMP-1 blotting, that reflect small functional cleavage products: dentine 
sialoprotein (DSP) and dentine phosphoprotein (DPP) [26]. Densitometry 
analysis revealed DSPP levels were increased by day 7 and reduced by day 14. 
Meanwhile, immunocytochemistry and confocal microscopy analysis revealed 
DSPP localisation to Golgi was induced upon ZnBG-CM treatment (Fig. 4). This 
implies that ZnBG increases intracellular DSPP protein levels, and 
subsequently processed in Golgi as reported previously [18]. Increases in DMP-
1 levels and secretion are detected as two fragments: N-terminal (37kDa) and 
C-terminal fragments (57kDa) [26], was also observed following ZnBG-CM 
treatment (Fig.4E). However, no changes in DMP-1 cellular localisation were 
observed in response to ZnBG-CM treatment. These findings lend support to 
the idea that ZnBGs in part induce odontogenic differentiation of hPDSCs. PCR 
analysis also revealed increase in both DSPP and DMP-1 mRNA expression 
along with osteogenic markers (RUNX2, BMP1, BSP, ON, OCN, and MEPE), 
which are crucial genes associated with critical roles in mineralisation [27-29]. 
These results are consistent with previous investigation showing that Zn added 
BG granules stimulate growth and osteogenic differentiation of MSCs via 
regulation of ALP activity and BSP expression [30]. Together, these findings 
suggest that ZnBGs can enhance differentiation of hDPSCs in a fashion similar 
to osteoblast differentiation. This in turn impacts on the mineralisation potential 
of hDPSCs, as observed in our studies by Alizarin Red S staining and SEM-
EDX (Fig. 5). Moreover, western blot analysis reveals that the expression of 
VEGF is increased following ZnBG-CM treatment. This is in agreement with a 
previous report that VEGF plays an essential role in the regulation of 
mineralisation by stimulating differentiation of MSCs [31]. VEGF has also been 
confirmed to promote odontogenic differentiation of hDPSCs in vitro [32, 33]. 
In a similar study, the stimulation of odontogenic differentiation of dental pulp 
cells following ZnBG incorporated cement treatment was reported. In addition, 
this ZnBG incorporated cement up-regulated the expression of VEGF and the 
increased the tubular structure in endothelial cells [34]. The findings in present 
study, in consistent with the previous investigation [34], clearly indicate that 
ZnBGs can promote the generation of mineralised nodules via up-regulation of 
VEGF in both osteogenic and odontogenic differentiation pathways in hDPSCs. 
It also raises the question, what effect are clinical treatments that contain Zn 
having on the local cells, and especially odontoblasts?
5. Conclusion
Stem cell-based regenerative endodontics is a new and exciting field that has 
the potential to transform the dental practice. In this study, novel zinc containing 
bioactive glasses were successfully designed and synthesised. Biological 
studies demonstrated activity of the odonto/osteogenic and VEGF pathways 
that might be the mechanism by which Zn induces the differentiation of hDPSCs. 
This study raises the intriguing possibility of using ZnBGs as therapeutic 
scaffolds in regenerative endodontics. 
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Figure Legends:
Figure 1. Effects of free Zn ion on hDPSCs. (A): MTT activity of hDPSCs treated with Zn (0-
20ppm). Data is presented as fold change upon comparison with Zn 0ppm group at day 1. (B): 
ALP activity of hDPSCs following Zn (0-20ppm) treatment. The ALP activity was measured in 
each group and normalised to cell number. (C): Crystal violet staining of hDPSCs after 10 days 
exposure to Zn (0-20ppm). Scale bar = 100 μm. All the data are expressed as mean±SD from 
three independent experiments. * indicates significance value of p<0.05 when compared to Zn 
0ppm group.  
Figure 2. Characterisation of ZnBGs. (A): ZnBG compositions, the network connectivity for all 
the ZnBGs are fixed at 2.1. (B): XRD patterns of all unreacted BGs confirm amorphous nature. 
(C) - (F): XRD pattern of ZnBGs after Tris buffer dissolution from 0 to 168 hrs, two peaks at 26 
and 32 2θo indicate apatite formation. (G) - (J): ICP-OES analysis of ZnBGs after immersion in 
Tris buffer for 168 hrs. All ionic (P, Ca, Si, and Zn) data in ppm was plotted as a function of time.
Figure 3. Effects of ZnBG on odontogenic differentiation. (A): Cell proliferation of hDPSCs 
treated with ZnBG-CMs was assessed by MTT activity assay. Data is presented as a fold change 
compared to negative control group at day 1 (B): ALP activity of hDPSCs following ZnBG-CMs 
treatment. The ALP activity was measured in each group and normalised to cell number. (C): 
Western blot analysis of intracellular DSPP and DMP-1 expression, GAPDH expression was used 
to determine the loading control. Lane 1-5: Negative control (NC), Zn0, Zn1, Zn2 and Zn3 BG-
CM, respectively. (D): Relative intensities of intracellular DSPP and DMP-1 to GAPDH were 
obtained, and then compared to NC group to determine the fold change. (E): Western blot 
analysis for secreted DSPP and DMP-1. Coomassie blue staining was used as loading control. 
The lanes setup is same as in (C). (F): Relative intensities of secreted extra cellular DSPP and 
DMP-1 were obtained by Coomassie blue staining, and then compared to NC group to 
determine fold changes. All data were expressed as mean±SD from three independent 
experiments, * indicates significance of p<0.05. 
Figure 4. ZnBGs regulate DSPP and DMP-1 localisation in hDPSCs. (A): Representative images 
show staining of DSPP and DMP-1 in red for hDPSCs. Scale bar = 8µm. (B): Representative 
images of DSPP and GM130 (Golgi marker) staining in hDPSCs following ZnBG-CM treatment. 
Images show DSPP (green) and Golgi (red) and cell nuclei (blue). Scale bar = 30µm. (C): The 
colocalisation of DSPP (green) and GM130 (red) in hDPSCs was quantified and represented in 
bar chart after treated with ZnBG-CMs Scale bar = 8µm. Data was expressed as mean±SD from 
three independent experiments, and * denotes p<0.05  significance where indicated.
Figure 5. ZnBG-CM regulates mineralisation and osteogenic differentiation of hDPSCs. (A): 
Representative images show Alizarin Red S staining indicating mineralisation (in red colour) of 
hDPSCs. (B): Quantification of Alizarin Red S staining in hDPSCs was presented as a fold change 
compared to negative control (NC) group. (C): SEM-EDX analysis of mineralised nodules 
generated in hDPSCs. (D)-(I): qPCR analysis of RUNX2, ON, OCN, BSP, MEPE and BMP-2 
expression in DPSCs following ZnBG-CM treatment for 7 and 14 days. The expression level of 
each gene was normalized to GAPDH (reference gene). Fold change was determined by 
comparing to NC group at day 7. (J): Western blot analysis of intracellular VEGF expression, 
and GAPDH levels were determined for loading control. Lane1-5: NC, Zn0, Zn1, Zn2 and Zn3-
BGCM.  (D): Relative intensities of VEGF in reference to GAPDH were determined and 
expressed as fold change in comparison to, NC.  All the data were expressed as mean±SD from 
three independent experiments, and the significance is denoted as *p<0.05, **p<0.01 where 
indicated.





